Мировой рынок лечения псориатического артрита – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка лечения псориатического артрита

Растущее число людей, страдающих от курения, ожирения, психического стресса и семейного анамнеза, являются основными факторами увеличения случаев псориатического артрита. Основные игроки рынка сосредоточены на получении одобрений от регулирующих органов для расширения своего портфеля продуктов. Псориатический артрит, по-видимому, поражает суставы только с одной стороны или с обеих сторон тела. Признаки и симптомы псориатического артрита часто похожи на признаки и симптомы ревматоидного артрита.  

Data Bridge Market Research анализирует темпы роста рынка лечения псориатического артрита в прогнозируемый период 2023-2030 гг. Ожидаемый среднегодовой темп роста рынка лечения псориатического артрита, как правило, составляет около 12% в указанный прогнозируемый период. Рынок был оценен в 9 миллиардов долларов США в 2022 году, и он вырастет до 22,28 миллиарда долларов США к 2030 году. В дополнение к рыночным данным, таким как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, рыночный отчет, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Масштаб и сегментация рынка лечения псориатического артрита

Market Definition

Psoriatic arthritis is a kind of arthritis that mostly affects people suffering from psoriasis, a chronic disease typically characterized by abnormal patches on skin. The major symptoms of psoriatic arthritis are inflammation and pain in joints. Majority of the people develop psoriasis first and are later diagnosed with psoriatic arthritis. However, the joint problems can sometimes begin before skin patches become visible.  

Psoriatic Arthritis Treatment Market Dynamics

Drivers

• High Prevalence of Obesity

Obesity and overweight are typically characterized as excessive or irregular fat accumulations that can harm one's health. In 2016, about 1.9 billion individuals aged 18 years and above were overweight. More than 650 million of those individuals were found to be obese. Around 39% of individuals aged 18 years and above were overweight in 2016, and 13% were obese. In 2020, 39 million kids under five were overweight or obese. Approximately 340 million kids and adolescents aged 5 to 19 years were considered overweight or obese in 2016. Thus, it is expected that the risk of psoriatic arthritis will increase as the prevalence of obesity grows. This boosts the market growth.

• Growing Research Activities

Major market players are primarily focused on gaining approvals from regulatory bodies to enhance their product portfolio. This is projected to boost the growth of the market during the forecast period. For instance, Janssen-Cilag International NV (Janssen) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the use of STELARA (ustekinumab), alone or in combination with methotrexate in July 2013, used for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) is not satisfying. Thus, this factor boosts the market growth.

Opportunities

• Increase Incidence of Psoriatic Arthritis

Psoriatic arthritis incidence has been steadily growing over the past few years, which has been associated with aging populations, genetic alterations, stressful lifestyles, and increasing life expectancy. As per the National Psoriasis Foundation, psoriasis and psoriatic arthritis affect millions of individuals in the U.S. and throughout the world. As per the latest research, more than 8 million individuals in the U.S. have psoriasis. According to the initiative on World Psoriasis Day, 125 million individuals globally, 2 to 3% of the entire population have psoriasis. It affects about 30% of patients with psoriasis. Thus, this prevalence rate demands high treatment rate and thus boosts the market growth.

• Increased Demand of Biologics

The increasing development of novel therapies in the psoriatic arthritis treatment market is boosting the growth of the market. This is inspiring new ideas among the major market players, promoting the development of the psoriatic arthritis treatment market. As per the latest study, the demand for DMARDs accounts for more than 3/4 of the market's overall value. Although the majority of psoriatic arthritis patients choose injectables as their favored method of treatment administration, the rising availability of high-end oral medications is increasing the appeal of orally delivered therapy. Thus, this factor boosts the market growth.

Restraints/Challenges

• Increased Availability of Substitute Treatments

Wide availability of alternate treatment for psoriatic arthritis is anticipated to impede the growth of the market during the forecast period. For instance, as per The Center Orthopedic & Neurosurgical Care & Research, nearly one million hip and knee replacement surgeries are performed in the U.S. every year, making it one of the most common orthopedic procedures performed. By 2030, total knee replacement surgeries are expected to grow 673% to 3.5 million procedures per year worldwide. Approximately 1/2 of the American adults are projected to develop knee osteoarthritis in at least one knee in their lifetime. Thus, this factor impede the market growth.

This psoriatic arthritis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psoriatic arthritis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, AbbVie Inc. announced that Health Canada had approved RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible Janus kinase (JAK) inhibitor for the treating adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).

Global Psoriatic Arthritis Treatment Market Scope

The psoriatic arthritis treatment market is segmented on the basis of diagnosis, types, treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-modifying Antirheumatic Drugs (DMARDs)
• Biologics
• Others

Types

• Oligoarticular
• Polyarticular
• others

Treatment

• Therapy
• Medication
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Psoriatic Arthritis Treatment Market Regional Analysis/Insights

The psoriatic arthritis treatment market is analyzed and market size insights and trends are provided by diagnosis, types, treatment, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the psoriatic arthritis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market because of an increase in the number of medications getting regulatory body approval. The increasing incidence of psoriatic arthritis, growing rates of rheumatoid arthritis, the development of advanced biologics and biosimilar for better psoriatic arthritis management, and the wide presence of major market players are boosting the market growth.  

Asia-Pacific is expected to account for the largest market share due to increasing prevalence cases psoriatic arthritis and the number of generic drugs. Furthermore, it has been shown that PsA patients in Asia have major rates of subclinical atherosclerosis and conventional cardiovascular risk factors.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Кроме того, при предоставлении прогнозного анализа данных по странам рассматриваются наличие и доступность глобальных брендов и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, влияние внутренних тарифов и торговых путей.   

Анализ конкурентной среды и доли мирового рынка лечения псориатического артрита

Конкурентная среда рынка лечения псориатического артрита содержит сведения по конкурентам. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании в применении. Приведенные выше данные касаются только фокуса компаний на рынке лечения псориатического артрита.

Ключевые игроки на рынке лечения псориатического артрита:

• Pfizer Inc. (США)
• Abbvie Inc. (США)
• Новартис АГ (Швейцария)
• Amgen Inc. (США)
• Boehringer Ingelheim International GmbH. (Германия)

• Merck & Co Inc. (США)
• Sun Pharmaceutical Industries Ltd. (Индия)
• Teva Pharmaceuticals Industries Ltd. (Израиль)
• АстраЗенека (Великобритания)
• Ampio Pharmaceuticals Inc. (США)
• Лилли (США)
• Mylan NV (США)
• Currax Pharmaceuticals LLC (США)
• Bayer AG (Германия)
• Антарес Фарма (США)
• Amgen Inc. (США)

SKU-52885